Triglycerides and remnant-c, but not LDL-c and HDL-c, were associated with MACE in a primary prevention cohort of high CV risk subjects with high prevalence of diabetes and obesity.
The recommendations in the 2019 ESC guidelines on management of diabetes and CVD have shifted from a glucose-centric approach towards an event-driven approach.
There are barriers to intensify treatment in T2DM patients leading to poor outcomes. Prof. Khunti presents findings from studies with GLP-1RA as a new, effective treatment option for T2DM patients with high CV risk.
Identifying and treating classic CV risk factors is important in patients with diabetes to reduce their CV risk. Prof. Hobbs discusses the classic CV risk factors one by one.
Compared to those who reported no alcohol intake, T2DM patients with moderate (>7 drinks/week) and heavy (>14 drinks/week) consumption had increased risk of elevated BP, hypertension grade I and hypertension grade 2.
Treatment with the PCSK9 inhibitor evolocumab reduced a composite of CV events compared to placebo in ASCVD patients with and without metabolic syndrome in a similar degree.
Treatment with the GLP-1RA dulaglutide for a median of 5.4 years resulted in a reduction of cognitive impairment compared to placebo in T2DM patients ≥50 years, in an exploratory analysis of REWIND.
A diagnostic model based on symptoms partly uncovered unrecognized AF, HF and CAD in participants from the Lifelines cohort study. This resulted in the development of an 11-item questionnaire for proactive screening.
Members of the Diabetes and Cardiovascular Disease EASD Study Group have published a perspective on issues of CV risk management in diabetes patients during the COVID-19 pandemic.
This study showed that the most frequent first manifestations of CV- and renal disease in T2D patients were HF and CKD, which were both associated with increased all-cause and CVD mortality risk.
A consensus document by a group of representatives from primary and secondary care has been published on the management of diabetes for patients at risk or with confirmed COVID-19.
Treatment with liraglutide plus lifestyle therapy led to a greater reduction in BMI standard-deviation score than placebo plus lifestyle therapy in adolescents with obesity.